CTI BioPharma Corp. announced that David R. Parkinson, M.D., has been appointed a Director of the company effective June 5, 2017. Dr. Parkinson has more than 20 years in oncology clinical development with executive leadership roles at major biotechnology and pharmaceutical companies. Additionally, Phillip M. Nudelman, Ph.D., has resigned as a member of the Board of Directors due to health reasons. Richard L. Love, a CTI BioPharma director, will act as Interim Chairman of the Board until the Board selects a permanent successor. Jack W. Singer, M.D., also resigned as a member of the Board. Both resignations were effective June 2, 2017. Dr. Singer will remain an employee of the company in his role as Executive Vice President, Chief Scientific Officer, Interim Chief Medical Officer and Global Head of Translational Medicine. Dr. Parkinson has served as President and Chief Executive Officer Essa Pharmaceuticals Inc. since 2016. Dr. Parkinson has served as a venture partner at New Enterprise Associates (NEA) Inc. since 2012 and in 2016 moved to the role of venture advisor to NEA.